PRESENTATION TITLE
Overcoming Acquired Resistance to EGFR Inhibition

PRESENTER(S)
Suresh Sakkarai Ramalingam, MBS, FACP, FASCO

Professor of Hematology and Medical Oncology, Roberto C. Goizueta Chair for Cancer Research

Assistant Dean for Cancer Research, Deputy Director of Winship Cancer Institute, Director, Division of

Medical Oncology, Emory University School of Medicine, Atlanta, GA

PRESENTER BIO

Suresh S. Ramalingam is Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine. He is also the Deputy Director of the Winship Cancer Institute of Emory University

Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for standard therapy of metastatic NSCLC. He also leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer. He has published more than 350 original manuscripts, review articles, editorials and book chapters. He serves as the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute. He is also the contact principal investigator for the ECOG-ACRIN Thoracic Malignancies Translational Science Center Award from the National Cancer Institute.

As the Deputy Director of Winship Cancer Institute, Dr. Ramalingam provides oversight for the scientific research programs and leads the Scientific Research Council. Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee and Deputy Chair for Therapeutics Programs at ECOG-ACRIN. He is the section editor for ‘Chest malignancies’ for ‘Cancer’ journal (American Cancer Society). Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI ‘Clinical Investigators Team Leadership Award’ (2010-12). Dr. Ramalingam serves as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) and as a member of the NCI Thoracic Malignancies Steering Committee. He is past president of the Georgia Society of Oncology and a former member of the Emory Healthcare board of directors.

Dr. Ramalingam received his medical degree at Kilpauk Medical College, Madras, India. He completed his residency in Internal Medicine at Wayne State University, Detroit, MI, where he also served as Chief Medical Resident. He then completed a fellowship in Hematology and Medical Oncology at the University of Pittsburgh Medical Center, Pittsburgh, PA.

VIEWING LOCATIONS
Via Zoom:  Link

LEARNING OBJECTIVES

• Review the role of EGFR TKI in lung cancer.
• Discuss acquired resistance mechanisms.
• Discuss novel strategies to overcome resistance.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.